PharmaBoardroom

Danish-Swedish Clinical Trial Collaboration: Better Together?

Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a…

Turkey: Biosimilars on the Rise

With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics…

Can Turkey Become a True Clinical Trials Hub?

Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global…

GEN: From Niche Distributor to Public Company

Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on…

Global Competitiveness: Where & Why Turkish Pharma Is…

When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the…

Solidarity: How COVID-19 Brought the Turkish R&D Ecosystem…

As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research…

Top 4 Priorities for Turkey’s Minister of Health

Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic.…

Turkey: Shifting Priorities – Clinical Trials, Biologics,…

There are perhaps no two words that better summarize the last few years in Turkish pharma than localization and pricing. But after years of investment…